Literature DB >> 12353058

LY404187: a novel positive allosteric modulator of AMPA receptors.

Jennifer C Quirk1, Eric S Nisenbaum.   

Abstract

LY404187 is a selective, potent and centrally active positive allosteric modulator of AMPA receptors. LY404187 preferentially acts at recombinant human homomeric GluR2 and GluR4 versus GluR1 and GluR3 AMPA receptors. In addition, LY404187 potentiates the flip splice variant of these AMPA receptors to a greater degree than the flop splice variant. In both recombinant and native AMPA receptors, potentiation by LY404187 displays a unique time-dependent growth that appears to involve a suppression of the desensitization process of these ion channels. LY404187 has been shown to enhance glutamatergic synaptic transmission both in vitro and in vivo. This augmentation of synaptic activity is due to the direct potentiation of AMPA receptor function, as well as an indirect recruitment of voltage-dependent NMDA receptor activity. Enhanced calcium influx through NMDA receptors is known to be a critical step in initiating long-term modifications in synaptic function (e.g., long-term potentiation, LTP). These modifications in synaptic function may be substrates for certain forms of memory encoding. Consistent with a recruitment of NMDA receptor activity, LY404187 has been shown to enhance performance in animal models of cognitive function requiring different mnemonic processes. These data suggest that AMPA receptor potentiators may be therapeutically beneficial for treating cognitive deficits in a variety of disorders, particularly those that are associated with reduced glutamatergic signaling such as schizophrenia. In addition, LY404187 has been demonstrated to be efficacious in animal models of behavioral despair that possess considerable predictive validity for antidepressant activity. Although the therapeutic efficacy of AMPA receptor potentiators in these and other diseases will ultimately be determined in the clinic, evidence suggests that the benefit of these compounds will be mediated by multiple mechanisms of action. These mechanisms include direct enhancement of AMPA receptor function, secondary mobilization of intracellular signaling cascades, and prolonged modulation of gene expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12353058      PMCID: PMC6741690          DOI: 10.1111/j.1527-3458.2002.tb00228.x

Source DB:  PubMed          Journal:  CNS Drug Rev        ISSN: 1080-563X


  24 in total

Review 1.  New medications for drug addiction hiding in glutamatergic neuroplasticity.

Authors:  P W Kalivas; N D Volkow
Journal:  Mol Psychiatry       Date:  2011-04-26       Impact factor: 15.992

Review 2.  Challenges for and current status of research into positive modulators of AMPA receptors.

Authors:  Simon E Ward; Benjamin D Bax; Mark Harries
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

Review 3.  Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Authors:  James N C Kew; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-25       Impact factor: 4.530

4.  Changes in AMPA subunit expression in the mouse brain after chronic treatment with the antidepressant maprotiline: a link between noradrenergic and glutamatergic function?

Authors:  Chay-Hoon Tan; Xin He; Jun Yang; Wei-Yi Ong
Journal:  Exp Brain Res       Date:  2005-11-30       Impact factor: 1.972

Review 5.  Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.

Authors:  Stefano Marenco; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.

Authors:  M L Woolley; K A Waters; J E Gartlon; L P Lacroix; C Jennings; F Shaughnessy; A Ong; D J Pemberton; M H Harries; E Southam; D N C Jones; L A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

7.  Progress in the development of new drugs in Alzheimer's disease.

Authors:  Antoine Piau; F Nourhashémi; C Hein; C Caillaud; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-01       Impact factor: 4.075

8.  Pharmacological characterization of N-[(2S)-5-(6-fluoro-3-pyridinyl)-2, 3-dihydro-1H-inden-2-yl]-2-propanesulfonamide: a novel, clinical AMPA receptor positive allosteric modulator.

Authors:  Simon E Ward; Paul Beswick; Novella Calcinaghi; Lee A Dawson; Jane Gartlon; Francesca Graziani; Declan N C Jones; Laurent Lacroix; M H Selina Mok; Beatrice Oliosi; Joanne Pardoe; Kathryn Starr; Marie L Woolley; Mark H Harries
Journal:  Br J Pharmacol       Date:  2017-01-31       Impact factor: 8.739

9.  A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents.

Authors:  Haijun Chen; Cheng Z Wang; Chunyong Ding; Christopher Wild; Bryan Copits; Geoffrey T Swanson; Kenneth M Johnson; Jia Zhou
Journal:  ChemMedChem       Date:  2012-12-20       Impact factor: 3.466

10.  Antidepressant interactions with the NMDA NR1-1b subunit.

Authors:  Richard Raabe; Lisa Gentile
Journal:  J Biophys       Date:  2008-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.